Indication name: Abdominal Aortic Aneurysm (AAA)
Abdominal Aortic Aneurysm
(AAA) – Market outlook, Epidemiology, Market Forecast and
Competitive Landscape Report – 2020 To 2030 (Markets covered: US, Germany,
France, Spain, United Kingdom, Italy, Japan & China).
An abdominal aortic aneurysm (AAA) is an
enlarged area in the lower part of the major vessel that supplies blood to the
body (aorta). The aorta runs from your heart through the center of the chest
and abdomen. The prognosis of the disease is poor, following the rupture of an
abdominal aortic aneurysm, the risk of death is approximately 80%. Most
patients die before reaching the hospital. In most patients, the outcome is
poor and surgical repair is only successful in 50% of cases with a ruptured
aneurysm.
Epidemiology-
The annual incidence of new AAA diagnoses is approximately 0.4 to 0.67 percent
in Western populations. This equates to 2.5 to 6.5 aneurysms per 1000
person-years. Age significantly impacts the incidence. As an example, in one
study, among men aged 65 to 74 years, the incidence was 55 per 100,000
person-years, increasing to 112 per 100,000 person-years for men aged 75 to 85
years, this further increased to 298 per 100,000 person-years for those older
than 85.
The market is expected to show a very strong growth throughout the study period
(2020 - 2030), growing at a CAGR of ~7.6%. Major drivers of the growth are the
newer pharmacotherapies which are expected to launch the market in the near
future.
Competitive landscape of Abdominal Aortic Aneurysm (AAA) includes
country specific approved as well as pipeline therapies. Any asset/ product
specific designation or review and Accelerated Approval are being tracked and
supplemented with analyst commentary.
Abdominal Aortic Aneurysm (AAA) Market Forecast: Patient
Based Forecast Model (MS. Excel Based Automated Dashboard)
which Data Inputs with sourcing, Market Event and Product Event, Country
specific Forecast Model, Market uptake and patient share uptake, Attribute
Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and
Insights.
KOLs insights of Abdominal
Aortic Aneurysm (AAA) across 8 MM market from center of Excellence/ Public/
Private hospitals participated in the study. Insights around current treatment
landscape, epidemiology, clinical characteristics, future treatment paradigm
and Unmet needs.
Read more: Abdominal Aortic Aneurysm (AAA) – Market
outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020
To 2030
S. No Asset
Company Stage
1 Alirocumab
Regeneron Pharmaceuticals Phase 3
2 Metformin Glucophage 500mg (IR)
tablets M90 Merck Serono GmbH, Germany Phase 3
3 Ticagrelor AstraZeneca Phase 2
1
No comments:
Post a Comment